Navigation Links
FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
Date:2/21/2008

Investigational antiplatelet agent submitted for treatment of patients with

acute coronary syndrome being managed with percutaneous coronary

intervention

TOKYO and INDIANAPOLIS, Feb. 21 /PRNewswire-FirstCall/ -- Daiichi Sankyo Company, Limited (TSE: 4568) and Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) accepted and designated Priority Review for the New Drug Application for prasugrel, for patients with acute coronary syndrome being managed with percutaneous coronary intervention (PCI). The NDA for prasugrel was submitted to the agency on Dec. 26, 2007.

A priority designation by the FDA sets the PDUFA (Prescription Drug User Fee Act) goal date. The PDUFA goal for priority applications is to have an action provided for 90 percent of applications within six months. FDA can take three different actions - approved, approvable with further discussion, or not approved.

"We are greatly pleased to learn that the FDA has determined the application meets its criteria for such a review, and we look forward to working with the agency as it continues its review process," said Dr. J. Anthony Ware, Lilly vice president for cardiovascular/acute care.

"If approved, prasugrel will provide physicians and acute coronary syndrome patients an alternative medicine that may further help reduce the risk of heart attacks," said John Alexander, M.D., M.P.H., global head of research and development, Daiichi Sankyo Company, Ltd.

About prasugrel

Daiichi Sankyo Company, Limited (TSE: 4568), and Eli Lilly and Company (NYSE:

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness
2. Chinese SFDA Grants Immtech Fast Track Status
3. Ethics Group Asks USAID Inspector General to Investigate Legality of Grants to Soros Groups
4. NTMir Announces Research Grants for Epidemiology and Household Water as Source of Infection
5. FDA Grants Approval to Extend U.S. Enrollment and Clinical Trial
6. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
7. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
8. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
9. ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
10. GlaxoSmithKline Accelerates Review of Exelixis XL880
11. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... LONDON , May 22, 2015 ... early phase clinical research unit with a worldwide ... respected for its frequent publications in peer reviewed ... and European stakeholders and regulators in discussions about ... results.      (Logo: http://photos.prnewswire.com/prnh/20150522/745125) , ...
(Date:5/21/2015)...  When Ryan Rendino first felt the ... neck, he figured it was a muscle ... from weight lifting. But the ... A series of doctor appointments followed ... Michel Kliot, MD , a Northwestern ...
(Date:5/21/2015)... 2015  CryoLife, Inc. (NYSE: CRY ), a ... cardiac and vascular surgery, announced today that its Board ... the second quarter 2015 of $0.03 per share of ... per share will be paid on June 19, 2015 ... 12, 2015.  The ex-dividend date for the quarterly dividend ...
Breaking Medicine Technology:Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 2Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 3Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 4CryoLife Announces Quarterly Cash Dividend for the Second Quarter 2015 2
... development of DG041 as an,effective anti-platelet that ... June 25, 2007 /PRNewswire-FirstCall/ --,deCODE genetics today ... company's Phase II developmental compound for the,prevention ... Phase IIa and,clinical pharmacology studies presented today ...
... Improving Glycemic Control and,Reducing Diabetic Cardiovascular Complications, ... VeroScience, LLC,in conjunction with its commercialization partner ... its Phase IIIb clinical trial,supporting the overall ... formulation of bromocriptine mesylate) in subjects,with type ...
Cached Medicine Technology:Positive Clinical Results for DG041 Lead Product Development,Highlights at deCODE R&D Event 2Positive Clinical Results for DG041 Lead Product Development,Highlights at deCODE R&D Event 3Positive Clinical Results for DG041 Lead Product Development,Highlights at deCODE R&D Event 4Positive Clinical Results for DG041 Lead Product Development,Highlights at deCODE R&D Event 5Positive Clinical Results for DG041 Lead Product Development,Highlights at deCODE R&D Event 6Phase IIIb Clinical Data Validate the Overall and Cardiovascular,Safety Profile of Cycloset (A Quick Release Formulation of,Bromocriptine Mesylate) in Patients with Type 2 Diabetes 2Phase IIIb Clinical Data Validate the Overall and Cardiovascular,Safety Profile of Cycloset (A Quick Release Formulation of,Bromocriptine Mesylate) in Patients with Type 2 Diabetes 3Phase IIIb Clinical Data Validate the Overall and Cardiovascular,Safety Profile of Cycloset (A Quick Release Formulation of,Bromocriptine Mesylate) in Patients with Type 2 Diabetes 4Phase IIIb Clinical Data Validate the Overall and Cardiovascular,Safety Profile of Cycloset (A Quick Release Formulation of,Bromocriptine Mesylate) in Patients with Type 2 Diabetes 5
(Date:5/24/2015)... Metamora, Michigan (PRWEB) May 24, 2015 ... for concerns about hair loss. Although it is unclear ... that there are environmental factors such as metabolism, nutritional ... contribute. Since they offer a comprehensive approach to evaluating ... and post-menopausal woman, they can help patients find a ...
(Date:5/24/2015)... Scientists with Cardno ChemRisk, a scientific ... compliance issues that may have raised the risk of ... just posted an article on the research. Click ... found airborne asbestos levels well above OSHA safety guidelines ... 2011. , “Asbestos compliance sampling data associated with the ...
(Date:5/24/2015)... Aliso Viejo, CA (PRWEB) May 24, 2015 ... for use in Final Cut Pro X. Utilize ProPin to ... locations in a given scene. , ProPin allows users ... are completely customizable in FCPX. With on-screen controls, video editors ... Studios allows users to pin and mark with absolute ease. , ...
(Date:5/24/2015)... May 24, 2015 ... CEO - The students were ... at the fourth annual A Day ... at Geneva National in Lake Geneva. ...     -Badger High School,         Jonathan Alfonso,         Bridget ...
(Date:5/23/2015)... Washington, D.C. (PRWEB) May 23, 2015 ... demonstration of powers of a youngster's yogic power learned ... by Sri Nithyananda Swami in Bangalore, India. , Yogamaatha, ... of more than 50 high profile professionals attending the ... D.C. by reading fluently -- blindfolded. , In ...
Breaking Medicine News(10 mins):Health News:Women's Excellence Now Treats Menopausal Hair Loss 2Health News:New Analysis Finds Too Many Employers Ignored OSHA Asbestos Guidelines, According to Surviving Mesothelioma 2Health News:Developers at Pixel Film Studios Release ProPin for Final Cut Pro X. 2Health News:Mercy Foundation Honors 16 Students for Making a Difference - Mercy Health System Javon Bea 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 3
... , FRIDAY, Feb. 4 (HealthDay News) -- Middle-aged breast cancer ... normally uncommon in women younger than 70, a new study ... that this may be because early menopause caused by breast ... weaken the bones by the time women reach middle age. ...
... be a feminine trait, but for women with peripheral artery ... point to the smaller calf muscles of women as a ... problems walking and climbing stairs sooner and faster than men ... the February 2011 issue of the Journal of the ...
... can prevent 90 percent of genital warts in men when ... the vaccine, according to a new multi-center study led by ... international clinical trial, which also found a nearly 66 percent ... prior exposure to these strains, provides the first reported results ...
... Reporter , THURSDAY, Feb. 3 (HealthDay News) -- While the ... new analysis backs the possibility that cold-like viruses might trigger ... studies, and concluded there is a strong association between enteroviruses ... with diabetes were 10 times more likely to have had ...
... people in employment, men and women who are unemployed suffer ... Why the un-employed should have health problems more often is ... current issue of Deutsches rzteblatt International (Dtsch Arztebl ... findings of the GEDA study. , The GEDA study (Gesundheit ...
... systematic review carried out by a team at the ... studies and concluded that there are benefits to mental ... environment. Their findings are published in the leading research ... February 2011. The research team, supported by the ...
Cached Medicine News:Health News:Breast Cancer Treatment May Lead to Hip Fracture 2Health News:Peripheral artery disease harder on women 2Health News:HPV vaccine works for boys: Study shows first clear benefits 2Health News:Cold Viruses Appear Linked to Type 1 Diabetes 2Health News:Cold Viruses Appear Linked to Type 1 Diabetes 3Health News:Review confirms benefits of outdoor exercise 2Health News:Review confirms benefits of outdoor exercise 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: